1189 Elucidating the effects of chemotherapy and immune checkpoint blockade on the activity of tarlatamab, a DLL3-targeting bispecific T cell engager molecule, in small cell lung cancer preclinical models

• Keegan Cooke,
• Jinghui Zhan,
• Juan Estrada,
• Matthias Friedrich,
• Ran You,
• Petra Deegen,
• Julie M Bailis

Affiliations

Keegan Cooke

4Amgen, MS: 15–2-A, CA, USA

Jinghui Zhan

2Amgen, Thousand Oaks, CA, USA

Juan Estrada

2Amgen, Thousand Oaks, CA, USA

Matthias Friedrich

3Amgen, Munich, Bavaria, Germany

Ran You

1Amgen, South San Francisco, CA, USA

Petra Deegen

3Amgen, Munich, Bavaria, Germany

Julie M Bailis

1Amgen, South San Francisco, CA, USA